All In Biotech

Drug Trial Radar · NCT06722729

A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease

A Late Phase II Clinical Trial of KDT-3594 in Patients With Advanced Parkinson's Disease With Levodopa

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

178

Actual

Start

Dec 16, 2024

Primary completion

Jan 14, 2026

Study completion Jan 14, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks in patients with advanced PD with levodopa.

Conditions

  • Parkinson Disease

Interventions

  • KDT-3594Drug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the MDS-UPDRS Part II+III (ON-time) total score at Week 17 of the treatment periodTime frame: Up to 17 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Tokyo and Other Japanese Cities, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.